Lurasidone is an atypical antipsychotic agent, specifically a benzisothiazol derivative, indicated for the treatment of schizophrenia and bipolar depression. By functioning as an antagonist at dopamine… Read more


















































Lurasidone is an atypical antipsychotic agent, specifically a benzisothiazol derivative, indicated for the treatment of schizophrenia and bipolar depression. By functioning as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, it helps regulate mood and cognitive function. This category provides a comprehensive range of reference standards, including Lurasidone API, its pharmacopeial and non-pharmacopeial impurities, degradation products, and stable isotope labelled compounds. These high-quality materials are essential for pharmaceutical laboratories performing impurity profiling, analytical method validation, and rigorous quality control. Using these characterized standards, chemists can accurately identify and quantify process-related impurities and metabolites, ensuring regulatory compliance and consistency throughout the drug development and manufacturing lifecycle. These reference materials support stability studies and routine testing, providing the necessary benchmarks to maintain the safety, potency, and efficacy of the final pharmaceutical product.